Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/31922
Title: Effects of dapagliflozin on congestion assessed by remote pulmonary artery pressure monitoring
Authors: MULLENS, Wilfried 
MARTENS, Pieter 
Forouzan, Omid
DAUW, Jeroen 
Vercammen, Jan
Luwel, Evert
Ceyssens, Wendy
Kockaerts, Veerle
AMELOOT, Koen 
DUPONT, Matthias 
Issue Date: 2020
Publisher: WILEY PERIODICALS, INC
Source: ESC HEART FAILURE, 7(5), p. 2071-2073
Abstract: Aims To explore the effects of dapagliflozin on congestion through CardioMEMS (Abbott Inc., Atlanta, USA) and Cordella (TM) pulmonary artery Sensor (Endotronix Inc., Lisle, Il, USA) devices, which are implantable systems that provide real-time remote monitoring of pulmonary artery pressure (PAP). Methods and results Single-centre open label observational pilot trial, to investigate the short-term effects of dapagliflozin in consecutive heart failure and reduced ejection fraction patients with elevated PAP between October and December 2019, previously implanted with CardioMEMS or Cordella (TM) Sensor. Changes in PAP were evaluated with an area under the curve methodology to estimate the total sum increase or decrease in pressures (mmHg/day) for 7 days before and after starting dapagliflozin relative to the first day of each period. Nine patients (72 +/- 10 years, N-terminal pro b-type natriuretic peptide 1027 +/- 510 pg/mL, estimated glomerular filtration rate 45 +/- 15 mL/kg/m2, left ventricular ejection fraction 35 +/- 10%), all on optimal guideline-directed therapy was included. The mean PAP was reduced from 42 +/- 9.16 to 38 +/- 9.95 mmHg with dapagliflozin therapy (P < 0.05). The average area under the curve for the week leading to dapagliflozin therapy remained unchanged compared to the drop observed for the week after therapy (P < 0.05). Interestingly, the drop in PAP occurred within the first 2 days of dapagliflozin and remained stable for the week following the start of the therapy. Conclusions This is the first study to demonstrate a direct effect of dapagliflozin on achieving effective hemodynamic decongestion, providing further mechanistic data regarding the potential mechanisms of sodium-glucose co-transporter-2 inhibitor benefits on heart failure.
Notes: Mullens, W (corresponding author), Ziekenhuis Oost Limburg, Dept Cardiol, Schiepse Bos 6, B-3600 Genk, Belgium.
wilfried.mullens@zol.be
Other: Mullens, W (corresponding author), Ziekenhuis Oost Limburg, Dept Cardiol, Schiepse Bos 6, B-3600 Genk, Belgium. wilfried.mullens@zol.be
Keywords: Dapagliflozin;Heart failure;MEMS;Pulmonary artery pressure
Document URI: http://hdl.handle.net/1942/31922
ISSN: 2055-5822
e-ISSN: 2055-5822
DOI: 10.1002/ehf2.12850
ISI #: WOS:000543135700001
Rights: © 2020 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made
Category: A1
Type: Journal Contribution
Validations: ecoom 2021
Appears in Collections:Research publications

Show full item record

WEB OF SCIENCETM
Citations

25
checked on Mar 29, 2024

Page view(s)

28
checked on Jul 22, 2022

Download(s)

6
checked on Jul 22, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.